KaloBios Completes Meeting with FDA for Benznidazole
December 12, 2016 07:30 ET
|
KaloBios Pharmaceuticals Inc.
BRISBANE, Calif., Dec. 12, 2016 (GLOBE NEWSWIRE) -- KaloBios Pharmaceuticals, Inc. (OTC:KBIO), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare...
KaloBios Highlights Priority Milestones in Letter to Stakeholders
December 05, 2016 07:30 ET
|
KaloBios Pharmaceuticals Inc.
BRISBANE, Calif., Dec. 05, 2016 (GLOBE NEWSWIRE) -- KaloBios Pharmaceuticals, Inc. (OTC:KBIO), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare...
KaloBios to Present at JMML International Symposium
November 29, 2016 07:30 ET
|
KaloBios Pharmaceuticals Inc.
BRISBANE, Calif., Nov. 29, 2016 (GLOBE NEWSWIRE) -- KaloBios Pharmaceuticals, Inc. (OTC:KBIO), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare...
KaloBios CEO to Present at the Priority Review Voucher Summit
October 31, 2016 07:30 ET
|
KaloBios Pharmaceuticals Inc.
BRISBANE, Calif., Oct. 31, 2016 (GLOBE NEWSWIRE) -- KaloBios Pharmaceuticals, Inc. (OTC:KBIO), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare...
KaloBios CEO to Participate in Pharmaceutical Strategy Conference
September 27, 2016 08:00 ET
|
KaloBios Pharmaceuticals Inc.
BRISBANE, Calif., Sept. 27, 2016 (GLOBE NEWSWIRE) -- KaloBios Pharmaceuticals, Inc. (OTC:KBIO), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare...
KaloBios Now Current on SEC Periodic Filings
September 23, 2016 16:45 ET
|
KaloBios Pharmaceuticals Inc.
BRISBANE, Calif., Sept. 23, 2016 (GLOBE NEWSWIRE) -- KaloBios Pharmaceuticals, Inc. (OTC:KBIO), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare...
KaloBios Files Outstanding 10-Q and 10-K for 2015
September 02, 2016 07:30 ET
|
KaloBios Pharmaceuticals Inc.
BRISBANE, Calif., Sept. 02, 2016 (GLOBE NEWSWIRE) -- KaloBios Pharmaceuticals, Inc. (OTC:KBIO), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare...
KaloBios Announces Martin Shkreli’s Sale of His Stake in the Company
August 29, 2016 09:25 ET
|
KaloBios Pharmaceuticals Inc.
Another crucial milestone in the KaloBios transformationShifts all focus and resources to near-term incremental value catalysts BRISBANE, Calif., Aug. 29, 2016 (GLOBE NEWSWIRE) --...
KaloBios Announces First Patient Dosed in Phase 1 Study of Lenzilumab for the Treatment of Chronic Myelomonocytic Leukemia
July 25, 2016 07:43 ET
|
KaloBios Pharmaceuticals Inc.
Lenzilumab offers promise for the treatment of rare leukemiaCompany turns full attention to executing its neglected and rare diseases pipeline ...
KaloBios Signs Definitive Agreement with Martin Shkreli Regarding Ownership of Shares
July 07, 2016 07:00 ET
|
KaloBios Pharmaceuticals Inc.
Provides mechanism for reduction of Mr. Shkreli’s ownership under certain circumstancesImmediately protects company by restricting his rights, actions as shareholder BRISBANE, Calif., July 07,...